SNY

🏥 Healthcare

Sanofi

Conservative #22Aggressive #276Low Risk

$46.76-1.31%

Day High$47.06

Day Low$46.51

Volume2.8M

Mkt Cap$113.6B

52W Low $4552W High $60

Market Cap

$113.6B

P/E Ratio

9.1

Sector avg: 19.1

Rev Growth

5.5%

Sector avg: 8.0%

Earnings Growth

40.5%

Profit Margin

18.2%

Sector avg: 16.9%

Debt/Equity

0.31

Score Breakdown

Overall Score83.4

Fundamental Score76.5

ML Score78.6

Score by Horizon

3 Month

78.5

6 Month

87.7

Primary

1 Year

92.3

Quality Assessment

Earnings Grade

Solid fundamentals with minor quality concerns

Quality Flags

High accrual ratio (-173.6%) — earnings quality concern

Position Sizing

Suggested Allocation

Confidence

high

Analysis Signals

Positive Signals

Fundamental: 76.5 (sector-relative)

ML percentile=78.6 (pre-ranked by batch)

Procyclicality dampener: ML weight reduced to 9.0% (S&P 500 return=25.0% > 20% (extended rally); Yield curve inverted (-10bp) — recession signal; Late-cycle score 2/3 → ML weight ×0.90)

Blend: 91% fund (76.5) + 9% ML (78.6) = 76.7

Market-cap adj: +3.5pt ($113.6B)

Flags: High accrual ratio (-173.6%) — earnings quality concern; R&D-adjusted ROIC: 10.6% (original: 11.8%). Drug Manufacturers - General has ~18% R&D intensity. Capitalizing R&D over 5 years increases invested capital by ~45%.

Risk Signals

Risk (low): Ultra-low vol 5.0% → +12pt stability bonus; Drawdown 14% → -2.4pt; Negative momentum -12% → -1.4pt

Quality: grade=B, penalty=-5

Sector Peer Comparison(Healthcare — 11 stocks in universe)

Stock	Score	P/E	Rev Growth	Margin	Mkt Cap
SNYSanofi	83.4	9.1	5.5%	18.2%	$113.6B
GMABGenmab A/S	90.3	13.1	22.8%	36.4%	$18.5B
EXELExelixis, Inc.	83.5	15.1	7.0%	33.7%	$11.7B
NBIXNeurocrine Biosciences, Inc.	81.1	26.5	21.4%	16.7%	$12.5B
GEHCGE HealthCare Technologies Inc.	80.5	17.7	4.8%	10.1%	$36.6B
ALKSAlkermes plc	80.0	16.5	-6.4%	23.9%	$5.5B
Sector Average	79.0	19.1	8.0%	16.9%	—

Why This Stock

HealthcareReasonable P/EHealthy profit marginAttractive valuation

Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.